» Articles » PMID: 38342767

The Association of Weight Loss from Anti-obesity Medications or Bariatric Surgery and Apnea-hypopnea Index in Obstructive Sleep Apnea

Overview
Journal Obes Rev
Specialty Endocrinology
Date 2024 Feb 11
PMID 38342767
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Weight loss is recommended for individuals with obstructive sleep apnea (OSA) and overweight or obesity, but there is limited evidence to guide the selection of weight management strategies for patients who do not lose sufficient weight with diet and lifestyle changes. We evaluated the relationship between weight loss caused by pharmacologic or surgical interventions and subsequent improvement in OSA by the apnea-hypopnea index (AHI).

Methods: PubMed, Cochrane CENTRAL, and EMBASE were searched for randomized trials comparing pharmacologic or surgical obesity interventions to usual care, placebo, or no treatment in adults with OSA. The association between percentage weight loss and AHI change between randomization and last follow-up was evaluated using meta-regression.

Prospero: CRD42022378853.

Results: Ten eligible trials (n = 854 patients) were included. Four (n = 211) assessed bariatric surgery, and 6 (n = 643) assessed pharmacologic interventions over a median follow-up of 13 months (interquartile range 6-26 months). The linear best estimate of the change in AHI is 0.45 events per hour (95% Confidence Interval 0.18 to 0.73 events per hour) for every 1% body weight lost.

Conclusions: Weight loss caused by medication or surgery caused a proportionate improvement of the AHI. Providers could consider extrapolating from this relationship when advising patients of the expected effects of other pharmacologic or surgical interventions without direct evidence in OSA.

Citing Articles

Bariatric surgery for treatment of morbid obesity in adults.

Park K, Jun K Korean J Intern Med. 2025; 40(1):24-39.

PMID: 39778524 PMC: 11725483. DOI: 10.3904/kjim.2024.219.


Metabolic and bariatric surgery for obstructive sleep apnoea syndrome: bibliometric analysis and visualisation from 1999 to 2023.

Jiang T, Zhang X, Wang H, Yi X BMJ Open. 2024; 14(10):e089233.

PMID: 39414275 PMC: 11481118. DOI: 10.1136/bmjopen-2024-089233.


Epigenetics and aging: relevance for sleep medicine.

Cortese R Curr Opin Pulm Med. 2024; 30(6):607-612.

PMID: 39082896 PMC: 11611687. DOI: 10.1097/MCP.0000000000001109.

References
1.
Bakker J, Weaver T, Parthasarathy S, Aloia M . Adherence to CPAP: What Should We Be Aiming For, and How Can We Get There?. Chest. 2019; 155(6):1272-1287. DOI: 10.1016/j.chest.2019.01.012. View

2.
Malhotra A, Ayappa I, Ayas N, Collop N, Kirsch D, McArdle N . Metrics of sleep apnea severity: beyond the apnea-hypopnea index. Sleep. 2021; 44(7). PMC: 8271129. DOI: 10.1093/sleep/zsab030. View

3.
Sprung V, Kemp G, Wilding J, Adams V, Murphy K, Burgess M . Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive.... BMJ Open. 2020; 10(7):e038856. PMC: 7380950. DOI: 10.1136/bmjopen-2020-038856. View

4.
Jastreboff A, Kushner R . New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annu Rev Med. 2023; 74:125-139. DOI: 10.1146/annurev-med-043021-014919. View

5.
Winslow D, Bowden C, DiDonato K, McCullough P . A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012; 35(11):1529-39. PMC: 3466800. DOI: 10.5665/sleep.2204. View